eMedicine Specialties > Radiology > Brain/Spine

Progressive Multifocal Leukodystrophy: Imaging

Author: Manohar Aribandi, MD, Academic Chief, Section of Neuroradiology, Department of Radiology, Geisinger Medical Center
Coauthor(s): Anil Kumar Aribandi, MBBS, MD, MRCP, Specialist Registrar, Department of Hematology, Manchester Royal Infirmary, UK
Contributor Information and Disclosures

Updated: Oct 14, 2009

Radiography

Findings

Radiographs have no role in the diagnosis of PML.

Computed Tomography


Nonenhanced CT of the head shows a hypoattenuatin...

Nonenhanced CT of the head shows a hypoattenuating lesion in the subcortical white matter. Note the characteristic scalloped lateral margin.

Nonenhanced CT of the head shows a hypoattenuatin...

Nonenhanced CT of the head shows a hypoattenuating lesion in the subcortical white matter. Note the characteristic scalloped lateral margin.


Findings

CT scans usually show several bilateral, asymmetric hypoattenuating foci of various sizes without mass effect or enhancement. The lesions may involve the periventricular white matter, subcortical white matter, or both. Subcortical U-fiber involvement results in lesions having a lateral scalloped margin that follows the gray matter–white matter junction.

Degree of Confidence

Although lesions may be seen on CT scanning, MRI offers superior sensitivity in the detection and characterization of the lesions. The diagnosis may be suspected with CT, but MRI is needed for a more confident exclusion of other differential considerations.

False Positives/Negatives

Artifacts; chronic, ischemic white-matter changes; and chronic infarcts may mimic true white-matter lesions of PML.

Magnetic Resonance Imaging


T2-weighted MRI in a patient infected with HIV de...

T2-weighted MRI in a patient infected with HIV demonstrates a hyperintense lesion in the left frontoparietal region in the subcortical and periventricular white matter. Biopsy confirmed progressive multifocal leukodystrophy.

T2-weighted MRI in a patient infected with HIV de...

T2-weighted MRI in a patient infected with HIV demonstrates a hyperintense lesion in the left frontoparietal region in the subcortical and periventricular white matter. Biopsy confirmed progressive multifocal leukodystrophy.


Contrast-enhanced T1-weighted MRI demonstrates a ...

Contrast-enhanced T1-weighted MRI demonstrates a hypointense lesion predominantly in a subcortical, left frontoparietal location. Note the characteristic absence of enhancement and lack of mass effect.

Contrast-enhanced T1-weighted MRI demonstrates a ...

Contrast-enhanced T1-weighted MRI demonstrates a hypointense lesion predominantly in a subcortical, left frontoparietal location. Note the characteristic absence of enhancement and lack of mass effect.


Fluid-attenuated inversion recovery (FLAIR) MRI c...

Fluid-attenuated inversion recovery (FLAIR) MRI corresponding to Image 1 shows the PML lesion with improved contrast after the suppression of cerebrospinal fluid signal intensity.

Fluid-attenuated inversion recovery (FLAIR) MRI c...

Fluid-attenuated inversion recovery (FLAIR) MRI corresponding to Image 1 shows the PML lesion with improved contrast after the suppression of cerebrospinal fluid signal intensity.


Fluid-attenuated inversion recovery (FLAIR) image...

Fluid-attenuated inversion recovery (FLAIR) images in a patient with HIV infection presenting with visual defects, aphasia, and balance problems. Patchy, confluent, and hyperintense lesions are seen in the left occipitotemporoparietal lobes in the subcortical and periventricular white matter. The patient's clinical and radiologic features suggested progressive multifocal leukodystrophy, though cerebrospinal fluid results for the JC virus were negative.

Fluid-attenuated inversion recovery (FLAIR) image...

Fluid-attenuated inversion recovery (FLAIR) images in a patient with HIV infection presenting with visual defects, aphasia, and balance problems. Patchy, confluent, and hyperintense lesions are seen in the left occipitotemporoparietal lobes in the subcortical and periventricular white matter. The patient's clinical and radiologic features suggested progressive multifocal leukodystrophy, though cerebrospinal fluid results for the JC virus were negative.


Findings

Findings on T1- and T2-weighted and fluid-attenuated inversion recovery images

MRI has far greater sensitivity than other studies in detecting the lesions of PML and in defining their extent of involvement. On T2W images, lesions appear hyperintense and typically involve the periventricular and subcortical white matter, having a characteristic scalloped lateral margin when they involve the subcortical white matter. Lesions are more conspicuously visualized on fluid-attenuated inversion recovery (FLAIR) images, appearing hyperintense against a background of suppressed CSF signal intensity.

Lesions appear hypointense and well demarcated on T1-weighted (T1W) images, though they may be isointense in the initial phase of the disease. Although the disease may involve any part of the brain, lesions typically occur in the parieto-occipital lobes. Lesions appear to start in the subcortical white matter before extending to the periventricular white matter. Mass effect is infrequently described and usually minimal and correlated with shorter survival when seen on initial studies.

Distribution of lesions

A multifocal distribution pattern is seen. This pattern may be unilateral, but more often, it is bilateral and asymmetric. Lesions may start small, but they eventually enlarge and coalesce. Posterior-fossa involvement is common and is seen in up to one third of patients. Synchronous lesions are usually seen in the supratentorial compartment, though in 10% of patients, lesions are confined to the structures of the posterior fossa. PML may also appear to involve the basal ganglia and deep gray-matter nuclei because of white-matter fibers in these structures. When present, involvement of the gray matter is a secondary finding. In rare cases, lesions are single and can occur anywhere in the brain, including the brainstem.

Findings on contrast-enhanced images

The lesions typically do not enhance and do not have mass effect; however, some reports describe lesions with faint peripheral enhancement or diffuse enhancement with mass effect, especially in the early stages. Enhancement could suggest a relatively good immune response and hence an improved prognosis.

Findings on diffusion-weighted images

On diffusion-weighted images (DWI), lesions can show restricted diffusion, though this is uncommon. The extent of abnormal diffusion appears to be correlated with the speed of clinical progression. Areas with DWI abnormality may correspond to areas that are actively infected by the virus at the time of imaging, but this has been uncommonly reported.

Prognostic utility of MRI in PML

Post et al studied the prognostic utility of MRI in PML.17 None of the MRI variables was predictive of patient survival, with the exception of mass effect, which was usually minimal, infrequent, and associated with decreased survival. Serial MRI studies showed progression of disease in 1-24 weeks, and a more rapid change was seen in many patients in just 9 weeks.

The authors suggested that findings of increasing atrophy, increasing confluence and extent of white-matter lesions, spread of disease across the corpus callosum, and increasing hypointensity of the lesions on follow-up T1W MRIs may be poor prognostic indicators or as failure of response to therapy. Stabilization or a decrease in the size of the lesion, clinical improvement, and loss JC viral detection on CSF PCR testing may indicate a response to therapy. However, improvements on MRI can lag clinical improvement by 2-6 months or even indicate temporary worsening.

In PML patients undergoing HAART, MRIs can show initial worsening in the first few months followed by stabilization and regression by 12 months. HAART consists of a combination of 3 or 4 anti-HIV drugs from the following classes: nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and protease inhibitors.

Thurnher et al reported 2 patients with long-term responses to HAART, apparent increased mass effect and enhancement before eventual improvement, and atrophy of the involved brain parenchyma.11 T1W MRIs but not FLAIR MRIs showed hypointensity. Two nonresponders initially had extensive changes, without enhancement or mass effect after the start of therapy. Their T1W MRIs also showed hypointense areas that were hyperintense on FLAIR images.

This increasing hypointensity on T1W MRIs might have been due to increasing demyelination, which appears hyperintense on FLAIR images. This finding might indicate a worsened prognosis. Increased T1W hypointensity in responders was due to gliosis and necrosis seen in burned-out lesions; this finding is hypointense on FLAIR images.

Berger et al18 found enhancement in 8.9% of short-term survivors in contrast to 50% in long-term survivors. Enhancement suggests an improved immune response and hence an improved prognosis.

In a study by Collazos et al,19 contrast enhancement was seen on images in patients with PML treated with HAART only when their CD4+ count increased. In these patients, the PML lesions changed from enhancing to nonenhancing on follow-up MRI after 3-6 months of therapy. Larger studies than this are needed to clearly identify the MRI changes after therapy and to confirm the utility of MRI in assessing the patient's prognosis and response to therapy.

Magnetic resonance spectroscopy

Evaluation of the PML lesions with magnetic resonance (MR) spectroscopy reveals reduced N -acetylaspartate (NAA) and creatine levels, increased choline levels, and an excess of lipids and sometimes of myo-inositol. In some cases, lactate is present. Cell membrane and myelin breakdown is the presumed cause of elevated choline levels, neuronal loss leads to decreased NAA concentrations, and glial-cells proliferation elevates myo-inositol values. The mild elevation of lactate and lipid levels may be due to the activity of macrophages and the breakdown products of myelin.

The elevation of choline and myo-inositol values is seen in the early phase of the disease. In the later phase all the metabolites are decreased. These metabolic abnormalities are not specific for PML and may be similar in other lesions complicating HIV disease.

Magnetization transfer imaging

PML lesions appear to have strongly reduced magnetization transfer ratios. According to Ernst et al,20 these features may help in distinguishing lesions from white-matter lesions of HIV leukoencephalopathy. Large prospective studies are needed to assess the utility of newer MR techniques, such as MR spectroscopy and magnetization transfer imaging, in the diagnosis and follow-up of PML.

Degree of Confidence

MRI has far greater sensitivity than that of other studies in depicting the lesions of PML and in defining their extent of involvement. Although MRI results may suggest the diagnosis of PML in the appropriate clinical setting, typical features of PML are often nonspecific, and other differential considerations, such as ischemic changes, HIV leukoencephalopathy, and gliotic changes from previous trauma, must be considered. When the lesions of PML are atypically enhancing or when they have mass effect, other lesions, such as those due to toxoplasmosis, lymphoma, or other intracranial masses should be considered.

The presence of multiple pathologies in immunocompromised conditions adds to the complexity of image interpretation. Infection coexisting with other opportunistic infection may be responsible for some atypical manifestations of the disease and for an apparent response to some form of therapy in some patients.

False Positives/Negatives

It is unusual for a normal variant to mimic PML lesions on MRI.

PML must be distinguished from HIV leukoencephalopathy. PML tends to be multifocal, with bilateral, asymmetric, and predominantly subcortical involvement. In comparison, HIV leukoencephalopathy tends to produce lesions that are usually diffuse, bilateral, and symmetric; these predominantly affect the periventricular white matter.

Diffuse cortical atrophy and ventricular dilatation are not predominant findings of PML and may be helpful in distinguishing from HIV leukoencephalopathy, which is usually associated with substantial atrophy. Lesions appear well defined and hypointense on T1W images, whereas they appear isointense and poorly defined in HIV leukoencephalopathy. Clinical correlation may be helpful, as patients with PML have progressive focal motor and sensory neurologic deficits, whereas those with HIV leukoencephalopathy present with global cognitive changes and dementia.

Nuclear Imaging

Findings

Nuclear medicine studies do not play a major role in the diagnosis of PML. However, Port et al described a case of PML in a patient with AIDS in whom MRIs of the lesion showed enhancement and mass effect, with increased thallium-201 uptake on single photon emission CT (SPECT).12 O'Mally et al21 had reported a case of PML with no uptake on201 Th SPECT.

Degree of Confidence

On thallium SPECT, photopenic lesions can be caused by any previous insult to the brain parenchyma, and hence, the differential considerations include a wide variety of causes. The uncommon observation of increased radiotracer uptake may be seen with lymphoma and is atypically found in some infections.

False Positives/Negatives

No anatomic variants have been described to mimic the lesions of PML, but cold lesions (eg, arachnoid cyst, porencephalic cyst) can conceivably appear as photopenic lesions similar to the lesions of PML.

Angiography

Findings

Angiography has no role in the diagnosis of PML. However, Nelson et al22 reported angiographic findings in 6 patients with PML. In 4, angiograms showed abnormal parenchymal blush of the affected region in the early to mid arterial phase and persisting into the venous phase. Associated arteriovenous shunting was also present. In only 1 of the 4 patients did MRI demonstrate enhancement.

On pathologic evaluation, intense perivascular inflammatory cellular infiltrates, angiogenesis, and gliosis were found in the patients with angiographic abnormalities, whereas changes were minimal in patients who did not have angiographic abnormalities.

Degree of Confidence

The findings of vascular blush and arteriovenous shunting on angiography are nonspecific and can be seen with infectious, neoplastic, vascular, and ischemic etiologies.

False Positives/Negatives

No known anatomic variants mimic the lesions of PML.

More on Progressive Multifocal Leukodystrophy

Overview: Progressive Multifocal Leukodystrophy
Imaging: Progressive Multifocal Leukodystrophy
Follow-up: Progressive Multifocal Leukodystrophy
Multimedia: Progressive Multifocal Leukodystrophy
References
Further Reading

References

  1. Anstrom KE, Mancall EL, Richardson EP Jr. Progressive multifocal leukoencephalopathy. Brain. 1958;81:93-127.

  2. ZuRhein GM. Association of papovavirus with a human demyelinating disease (progressive multifocal leukoencephalopathy). Prog Med Virol. 1969;11:185-247.

  3. Padgett BL, Walker DL, ZuRhein GM, et al. Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. Lancet. 1971;1(7712):1257-1260. [Medline].

  4. Hua-Chuan Z, Lei Y, Lei C, Yi-Fu G, Yasuo T. Mapping the history and current situation of research on John Cunningham virus- a bibliometric analysis. BMC Infect Dis. Mar 11 2009;9(1):28. [Medline].

  5. Wang Y, Kirby JE, Qian Q. Effective use of JC virus PCR for diagnosis of progressive multifocal leukoencephalopathy. J Med Microbiol. Feb 2009;58:253-5. [Medline].

  6. Grabowski MK, Viscidi RP, Margolick JB, Jacobson LP, Shah KV. Investigation of pre-diagnostic virological markers for progressive multifocal leukoencephalopathy in human immunodeficiency virus-infected patients. J Med Virol. Jul 2009;81(7):1140-50. [Medline].

  7. Mofenson LM, Brady MT, Danner SP, Dominguez KL, Hazra R, Handelsman E, et al. Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. MMWR Recomm Rep. Sep 4 2009;58:1-166. [Medline].

  8. Hernández B, Dronda F, Moreno S. Treatment options for AIDS patients with progressive multifocal leukoencephalopathy. Expert Opin Pharmacother. Feb 2009;10(3):403-16. [Medline].

  9. Tan CS, Dezube BJ, Bhargava P, Autissier P, Wüthrich C, Miller J, et al. Detection of JC virus DNA and proteins in the bone marrow of HIV-positive and HIV-negative patients: implications for viral latency and neurotropic transformation. J Infect Dis. Mar 15 2009;199(6):881-8. [Medline].

  10. Focosi D, Kast RE, Maggi F, Ceccherini-Nelli L, Petrini M. JC virus DNA in healthy brain tissue: a challenge for progressive multifocal leukoencephalopathy diagnosis. Ann Neurol. Feb 2009;65(2):230; author reply 230-31. [Medline].

  11. Thurnher MM, Post MJ, Rieger A, et al. Initial and follow-up MR imaging findings in AIDS-related progressive multifocal leukoencephalopathy treated with highly active antiretroviral therapy. AJNR Am J Neuroradiol. 2001;22(5):977-84. [Medline].

  12. Port JD, Miseljic S, Lee RR, et al. Progressive multifocal leukoencephalopathy demonstrating contrast enhancement on MRI and uptake of thallium-201: a case report. Neuroradiology. 1999;41 (12):895-898. [Medline].

  13. Iranzo A, Moreno A, Pujol J, et al. Proton magnetic resonance spectroscopy pattern of progressive multifocal leukoencephalopathy in AIDS. J Neurol Neurosurg Psychiatry. Apr 1999;66(4):520-3. [Medline].

  14. Ohta K, Obara K, Sakauchi M, et al. Lesion extension detected by diffusion-weighted magnetic resonance imaging in progressive multifocal leukoencephalopathy. J Neurol. 2001;248(9):809-811. [Medline].

  15. Simone IL, Federico F, Tortorella C, et al. Localized 1H-MR spectroscopy for metabolic characterisation of diffuse and focal brain lesions in patients infected with HIV. J Neurol Neurosurg Psychiatry. Apr 1998;64(4):516-23. [Medline].

  16. Sakai M, Inoue Y, Aoki S, Sirasaka T, Uehira T, Takahama S, et al. Follow-up magnetic resonance imaging findings in patients with progressive multifocal leukoencephalopathy: evaluation of long-term survivors under highly active antiretroviral therapy. Jpn J Radiol. Feb 2009;27(2):69-77. [Medline].

  17. Post MJ, Yiannoutsos C, Simpson D, et al. Progressive multifocal leukoencephalopathy in AIDS: are there any MR findings useful to patient management and predictive of patient survival? AIDS Clinical Trials Group, 243 Team. AJNR Am J Neuroradiol. 1999;20(10):1896-1906. [Medline].

  18. Berger JR, Levy RM, Flomenhoft D, Dobbs M. Predictive factors for prolonged survival in acquired immunodeficiency syndrome-associated progressive multifocal leukoencephalopathy. Ann Neurol. Sep 1998;44(3):341-9. [Medline].

  19. Collazos J, Mayo J, Martínez E, et al. Contrast-enhancing progressive multifocal leukoencephalopathy as an immune reconstitution event in AIDS patients. AIDS. Jul 30 1999;13(11):1426-8. [Medline].

  20. Ernst T, Chang L, Witt M, et al. Progressive multifocal leukoencephalopathy and human immunodeficiency virus-associated white matter lesions in AIDS: magnetization transfer MR imaging. Radiology. Feb 1999;210(2):539-43. [Medline].

  21. O''Malley JP, Ziessman HA, Kumar PN, et al. Diagnosis of intracranial lymphoma in patients with AIDS: value of 201TI single-photon emission computed tomography. AJR Am J Roentgenol. Aug 1994;163(2):417-21. [Medline].

  22. Nelson PK, Masters LT, Zagzag D, et al. Angiographic abnormalities in progressive multifocal leukoencephalopathy: an explanation based on neuropathologic findings. AJNR Am J Neuroradiol. Mar 1999;20(3):487-94. [Medline].

  23. Berger JR, Major EO. Progressive multifocal leukoencephalopathy. Semin Neurol. 1999;19(2):193-200. [Medline].

  24. Berger JR, Pall L, Lanska D, Whiteman M. Progressive multifocal leukoencephalopathy in patients with HIV infection. J Neurovirol. 1998;4(1):59-68. [Medline].

  25. Chang L, Ernst T, Tornatore C, et al. Metabolite abnormalities in progressive multifocal leukoencephalopathy by proton magnetic resonance spectroscopy. Neurology. Apr 1997;48(4):836-45. [Medline].

  26. Dworkin MS. A review of progressive multifocal leukoencephalopathy in persons with and without AIDS. Curr Clin Top Infect Dis. 2002;22:181-95. [Medline].

  27. Kastrup O, Maschke M, Diener HC, et al. Progressive multifocal leukoencephalopathy limited to the brain stem. Neuroradiology. Mar 2002;44(3):227-9. [Medline].

  28. Kotecha N, George MJ, Smith TW, et al. Enhancing progressive multifocal leukoencephalopathy: an indicator of improved immune status?. Am J Med. Dec 1998;105(6):541-3. [Medline].

  29. Mader I, Herrlinger U, Klose U, et al. Progressive multifocal leukoencephalopathy: analysis of lesion development with diffusion-weighted MRI. Neuroradiology. Oct 2003;45(10):717-21. [Medline].

  30. Mayo J, Collazos J, Martínez E. Progressive multifocal leukoencephalopathy following initiation of highly active antiretroviral therapy. AIDS. Sep 10 1998;12(13):1720-2. [Medline].

  31. Nicoli F, Chave B, Peragut JC, Gastaut JL. Efficacy of cytarabine in progressive multifocal leucoencephalopathy in AIDS. Lancet. 1992;339(8788):306. [Medline].

  32. Portegies P, Algra PR, Hollak CE, et al. Response to cytarabine in progressive multifocal leucoencephalopathy in AIDS. Lancet. 1991;337(8742):680-681. [Medline].

  33. Sadler M, Nelson MR. Progressive multifocal leukoencephalopathy in HIV. Int J STD AIDS. 1997;8(6):351-357. [Medline].

Keywords

progressive multifocal leukodystrophy, PML, progressive multifocal leukoencephalopathy, acquired immune deficiency, AIDS, multifocal demyelination, JC virus,

Contributor Information and Disclosures

Author

Manohar Aribandi, MD, Academic Chief, Section of Neuroradiology, Department of Radiology, Geisinger Medical Center
Manohar Aribandi, MD is a member of the following medical societies: American Society of Neuroradiology
Disclosure: Nothing to disclose.

Coauthor(s)

Anil Kumar Aribandi, MBBS, MD, MRCP, Specialist Registrar, Department of Hematology, Manchester Royal Infirmary, UK
Disclosure: Nothing to disclose.

Medical Editor

Mahesh R Patel, MD, Chief, MRI, Department of Diagnostic Imaging, Santa Clara Valley Medial Center
Mahesh R Patel, MD is a member of the following medical societies: American Roentgen Ray Society, American Society of Neuroradiology, and Radiological Society of North America
Disclosure: Nothing to disclose.

Pharmacy Editor

Bernard D Coombs, MB, ChB, PhD, Consulting Staff, Department of Specialist Rehabilitation Services, Hutt Valley District Health Board, New Zealand
Disclosure: Nothing to disclose.

Managing Editor

Robert L DeLaPaz, MD, Director, Professor, Department of Radiology, Division of Neuroradiology, Columbia University
Robert L DeLaPaz, MD is a member of the following medical societies: American Society of Neuroradiology, Association of University Radiologists, and Radiological Society of North America
Disclosure: Nothing to disclose.

CME Editor

Robert M Krasny, MD, Resolution Imaging Medical Corporation
Robert M Krasny, MD is a member of the following medical societies: American Roentgen Ray Society and Radiological Society of North America
Disclosure: Nothing to disclose.

Chief Editor

L Gill Naul, MD, Professor and Head, Department of Radiology, Texas A&M University College of Medicine; Chair, Department of Radiology, Chief, Section of Magnetic Resonance Imaging, Scott and White Memorial Hospital and Clinic
L Gill Naul, MD is a member of the following medical societies: American College of Radiology, American Medical Association, American Roentgen Ray Society, Radiological Society of North America, and Texas Medical Association
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.